Cargando…

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant hematological disorder arising in the thymus from T-cell progenitors. T-ALL mainly affects children and young adults, and remains fatal in 20% of adolescents and 50% of adults, despite progress in polychemotherapy protocols. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bressanin, Daniela, Evangelisti, Camilla, Ricci, Francesca, Tabellini, Giovanna, Chiarini, Francesca, Tazzari, Pier Luigi, Melchionda, Fraia, Buontempo, Francesca, Pagliaro, Pasqualepaolo, Pession, Andrea, McCubrey, James A., Martelli, Alberto M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478458/ https://www.ncbi.nlm.nih.gov/pubmed/22885370

Ejemplares similares

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
por: Martelli, Alberto M., et al.
Publicado: (2012)

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics
por: Evangelisti, Cecilia, et al.
Publicado: (2014)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia
por: Astolfi, Annalisa, et al.
Publicado: (2013)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
por: Martelli, Alberto M., et al.
Publicado: (2023)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia
por: Chiarini, Francesca, et al.
Publicado: (2020)

Human cadaver multipotent stromal/stem cells isolated from arteries stored in liquid nitrogen for 5 years
por: Valente, Sabrina, et al.
Publicado: (2014)

The Cutting Edge: The Role of mTOR Signaling in Laminopathies
por: Chiarini, Francesca, et al.
Publicado: (2019)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015)

The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response
por: Martelli, Alberto M., et al.
Publicado: (2019)

Negative pressure treatment for necrotizing fasciitis after chemotherapy
por: Melchionda, Fraia, et al.
Publicado: (2011)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

Shiga Toxin 1, as DNA Repair Inhibitor, Synergistically Potentiates the Activity of the Anticancer Drug, Mafosfamide, on Raji Cells
por: Brigotti, Maurizio, et al.
Publicado: (2013)

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008)

Neutrophil Gelatinase-Associated Lipocalin Increases HLA-G(+)/FoxP3(+) T-Regulatory Cell Population in an In Vitro Model of PBMC
por: La Manna, Gaetano, et al.
Publicado: (2014)

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
por: Simioni, Carolina, et al.
Publicado: (2015)

HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells
por: Gibellini, Davide, et al.
Publicado: (2011)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

GSK-3β: A key regulator of breast cancer drug resistance
por: Martelli, Alberto M, et al.
Publicado: (2014)

Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature
por: Serravalle, Salvatore, et al.
Publicado: (2016)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
por: Ultimo, Simona, et al.
Publicado: (2017)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

BCOR involvement in cancer
por: Astolfi, Annalisa, et al.
Publicado: (2019)

B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
por: Ratti, Stefano, et al.
Publicado: (2020)

Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK)
por: Fiore, Michele, et al.
Publicado: (2023)

Mutational analysis of ribosomal proteins in a cohort of pediatric patients with T-cell acute lymphoblastic leukemia reveals Q123R, a novel mutation in RPL10
por: Bacci, Lorenza, et al.
Publicado: (2022)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ivqc41bvnvheibkudait1cr4ir